Table 1.
Clinical characteristics of 67 patients with high-dose daptomycin therapy
| Characteristica |
Daptomycin dose (mg/kg) |
|
|
|---|---|---|---|
| ≤ 8 (n = 41) | >8 (n = 26) | P value | |
| Age, years |
56 (18–89) |
58.5 (22–87) |
0.57 |
| Male (%) |
23 (56.1%) |
17 (65.4%) |
0.45 |
| Weight, kg |
56 (37–89) |
61.5 (42–87) |
0.13 |
| Creatinine clearance, mL/min |
38 (5–263) |
57.5 (10–210) |
0.54 |
| Indwelling catheter useb |
31 (75.6%) |
16 (61.5%) |
0.22 |
| Surgery within 3 months |
13 (31.7%) |
10 (38.5%) |
0.57 |
| Underlying diseases |
|
|
|
| Diabetes mellitus |
14 (34.1%) |
8 (30.8%) |
0.77 |
| Cirrhosis of liver |
1 (2.4%) |
4 (15.4%) |
0.14 |
| ESRD |
11 (26.8%) |
7 (26.9%) |
0.99 |
| Heart failure |
11 (26.8%) |
11 (42.3%) |
0.19 |
| Chronic lung disease |
5 (12.2%) |
3 (11.5%) |
0.94 |
| Malignancy |
17 (41.5%) |
6 (23.1%) |
0.12 |
| Charlson index |
4 (0–11) |
3.5 (0–11) |
0.46 |
| Pitt bacteremia scorec |
4 (0–10) |
3 (0–7) |
0.85 |
| ICU stay |
24 (58.5%) |
17 (65.4%) |
0.58 |
| SOFA scored |
7 (2–17) |
8 (0–17) |
0.49 |
| Ventilator use |
19 (46.3%) |
14 (53.8%) |
0.55 |
| Previous anti-gram positive antibiotic |
|
|
|
| Vancomycin |
28 (68.3%) |
22 (84.6%) |
0.14 |
| Teicoplanin |
13 (31.7%) |
9 (34.6%) |
0.81 |
| Linezolid | 5 (12.2%) | 4 (15.4%) | 0.71 |
a Data are median (range) for continuous variables.
b Including central venous catheter, port-A catheter, Hickman catheter, temporal pacemaker, and intra-aortic balloon pump.
c Only for bacteremic patients.
d Only for ICU patients.
ESRD, end-stage renal disease; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; VHD, valvular heart disease.